Development and validation of an accurate quantitative real-time polymerase chain reaction–based assay for human blastocyst comprehensive chromosomal aneuploidy screening

Treff, Nathan R.; Tao, Xin; Ferry, K.M.; Su, Jing; Taylor, Deanne; Scott, Richard T.

doi:10.1016/j.fertnstert.2012.01.115

Cited by 208 publications

(146 citation statements)

References 21 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Their technique, therefore, potentially eliminates any need for cryopreservation [19]. Using whole genome amplification, Yang et al performed analysis in time for embryo transfer on day-6, using a proprietary so-called SurePlex DNA amplification system (BlueGnome Ltd; Cambridge, UK) [16].…”

Section: Search Strategymentioning

confidence: 99%

A review of, and commentary on, the ongoing second clinical introduction of preimplantation genetic screening (PGS) to routine IVF practice

Gleicher

Barad

2012

J Assist Reprod Genet

View full text Add to dashboard Cite

Section: Search Strategymentioning

confidence: 99%

A review of, and commentary on, the ongoing second clinical introduction of preimplantation genetic screening (PGS) to routine IVF practice

Gleicher

Barad

2012

J Assist Reprod Genet

View full text Add to dashboard Cite

“…Quantitative PCR (qPCR) or real-time PCR (RT-PCR) is a polymerase chain reaction assay that can identify whole chromosome aneuploidy by detecting the copy number of each [47,48]. It does this by comparing three or four locus-specific amplicons along each chromosome to a reference gene from the same chromosome (Fig.…”

Section: Quantitative Pcr or Real-time Pcrmentioning

confidence: 99%

“…3). This assay can easily identify aneuploidy for all 23 pairs of chromosomes in a rapid fashion (4-12 h; depending upon the number of samples analyzed), but it is very labor intensive and automation is highly recommended [47,48]. qPCR is unable to accurately identify structural chromosome aberrations but can identify triploidy.…”

Section: Quantitative Pcr or Real-time Pcrmentioning

confidence: 99%

See 1 more Smart Citation

Preimplantation genetic testing for aneuploidy: what technology should you use and what are the differences?

Brezina

Anchan

Kearns

2016

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The purpose of the review was to define the various diagnostic platforms currently available to perform preimplantation genetic testing for aneuploidy and describe in a clear and balanced manner the various strengths and weaknesses of these technologies. Methods A systematic literature review was conducted. We used the terms "preimplantation genetic testing," "preimplantation genetic diagnosis," "preimplantation genetic screening, " "preimplantation genetic diagnosis for aneuploidy," "PGD," "PGS," and "PGD-A" to search through PubMed, ScienceDirect, and Google Scholar from the year 2000 to April 2016. Bibliographies of articles were also searched for relevant studies. When possible, larger randomized controlled trials were used. However, for some emerging data, only data from meeting abstracts were available. Results PGS is emerging as one of the most valuable tools to enhance pregnancy success with assisted reproductive technologies. While all of the current diagnostic platforms currently available have various advantages and disadvantages, some platforms, such as next-generation sequencing (NGS), are capable of evaluating far more data points than has been previously possible. The emerging complexity of different technologies, especially with the utilization of more sophisticated tools such as NGS, requires an understanding by clinicians in order to request the best test for their patients.. Conclusion Ultimately, the choice of which diagnostic platform is utilized should be individualized to the needs of both the clinic and the patient. Such a decision must incorporate the risk tolerance of both the patient and provider, fiscal considerations, and other factors such as the ability to counsel patients on their testing results and how these may or may not impact clinical outcomes.

show abstract

“…Multiple studies have shown that highly graded embryos can be chromosomally abnormal [13,14,15,16] and aneuploidy is the leading cause of failed implantation and miscarriage [17,18,19,20,21,22,23]. While initial attempts at preimplantation genetic screening (PGS) in cleavage stage embryos failed to demonstrate improved pregnancy rates, trophectoderm biopsy coupled with comprehensive chromosomal screening (CCS) [24,25] have yielded encouraging results [26,27,28,29,30].…”

Section: Introductionmentioning

confidence: 99%

A greater number of euploid blastocysts in a given cohort predicts excellent outcomes in single embryo transfer cycles

Morin

Melzer-Ross²,

McCulloh

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose This multicentered retrospective study analyzed whether the quantity of euploid blastocysts in a given cohort after comprehensive chromosomal screening can be used to identify candidates for single embryo transfer. Methods Blastocysts from 437 patients underwent trophectoderm biopsy followed by array comparative genomic hybridization. Embryos were then selected for single or double embryo transfer. The number of euploid blastocysts produced and transferred for each patient was recorded, as was clinical pregnancy rate and multiple gestation rate. Results In patients with e3 euploid blastocysts, clinical pregnancy rate was higher in double, compared to single embryo transfers. However, in patients with Q4 euploid blastocysts, clinical pregnancy rate was not reduced with single embryo transfer was performed, whereas the multiple gestation rate was greatly reduced. Conclusions Size of the euploid embryo cohort is a marker for success in single embryo transfer cycles. Patients who produce at least four euploid blastocysts are outstanding candidates for single embryo transer.

show abstract

Development and validation of an accurate quantitative real-time polymerase chain reaction–based assay for human blastocyst comprehensive chromosomal aneuploidy screening

Cited by 208 publications

References 21 publications

A review of, and commentary on, the ongoing second clinical introduction of preimplantation genetic screening (PGS) to routine IVF practice

A review of, and commentary on, the ongoing second clinical introduction of preimplantation genetic screening (PGS) to routine IVF practice

Preimplantation genetic testing for aneuploidy: what technology should you use and what are the differences?

A greater number of euploid blastocysts in a given cohort predicts excellent outcomes in single embryo transfer cycles

Contact Info

Product

Resources

About